

Association of P-Wave Axis With Incident Atrial Fibrillation in Diabetes Mellitus (from the ACCORD Trial)



Karanpreet K. Dhaliwal, MS^a, Bharathi Upadhy, MD^a, Elsayed Z. Soliman, MD, MSc, MS^{a,b}, Elijah H. Beaty, MD, MPH^a, Joseph Yeboah, MD, MSc^a, Prashant D. Bhav, MD^a, Sean P. Whalen, MD^a, and Matthew J. Singleton, MD, MBE, MHS, MSc^{a,*}

Abnormal P-wave axis may reflect preclinical atrial dysfunction and has been associated with an increased risk of incident atrial fibrillation (AF) in the general population. Patients with diabetes mellitus (DM) have a higher prevalence of AF, but the association of abnormal P-wave axis and the risk of incident AF in those with diabetes has not been previously explored. For this analysis, we included 8,965 eligible participants from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. P-wave axis was automatically measured on study electrocardiogram and visually confirmed, with the normal range being between 0° and 75°. At baseline, 8% of the study population had an abnormal P-wave axis. During 43,856 person-years of follow-up, there were 145 cases of incident AF. Using multivariable-adjusted Cox proportional hazards models, participants with abnormal P-wave axis had an increased risk of incident AF (hazard ratio 2.65, 95% confidence interval 1.76 to 3.99, $p < 0.0001$). Findings were similar in prespecified subgroups, without evidence of effect modification. Both left- and right-axis deviation of the P-wave were associated with incident AF. Our results suggest that abnormal P-wave axis is associated with incident AF in those with DM and that this relation is conserved in prespecified subgroups. There may be utility in considering P-wave axis values from routine ECGs in these patients. © 2020 Elsevier Inc. All rights reserved. (Am J Cardiol 2020;128:191–195)

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia with an incidence that increases with age, which may reflect the burden of the progressive accumulation of predisposing comorbidities.^{1–3} Studies have shown that diabetes mellitus (DM) is an independent risk factor for developing AF.^{4–6} Although no screening method for risk of developing AF has been agreed upon, recent studies indicate that the P-wave axis (PWA), historically used in screening for lung disease, may be useful in predicting incidence of arrhythmias.^{2,7–11} The PWA is readily available, yet scarcely utilized, on routine ECGs. Normal PWA is typically defined between 0 and +75°. ¹² Several studies examining this in the general population discovered that abnormal PWA is associated with an increased risk of AF and of all-cause and cardiovascular mortality.^{10,13,14} There appears to be a parallel effect between abnormal PWA and DM on the incidence of AF, yet this association with PWA has not been studied specifically in those with diabetes. Therefore, we examined the

relationship between abnormal PWA and incident AF in participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Methods

This is a retrospective analysis of prospectively-collected data from the ACCORD trial. The design and conduct of the ACCORD trial has been previously described.¹⁵ Briefly, 10,251 individuals with type 2 DM from 77 sites across the United States and Canada were randomly assigned to intensive or standard glucose-lowering methods and monitored for health outcomes. The participants were also enrolled in either a lipid trial or a blood pressure trial to assess a total of 3 risk factors for cardiovascular disease, namely hyperglycemia, dyslipidemia, and hypertension. An electrocardiogram (ECG) was obtained in each participant at baseline, every 2 years, and at the end of the trial. Those with baseline ECGs of inadequate quality for assessment of PWA or AF at baseline were excluded. The reported PWA was used for analysis, with normal being defined as a value between 0 and 75°.

Study ECGs were obtained by trained electrocardiographers via standardized protocol on a GE Marquette (Milwaukee, Wisconsin) MAC 1200 electrocardiograph at a sampling rate of 500 Hz. All ECGs were digitally-transmitted to a central core laboratory for processing and coding—the Epidemiological Cardiology Research Center (EPI-CARE) at Wake Forest School of Medicine. Study ECGs were visually checked for quality and then automatically

^aSection of Cardiology, Department of Internal Medicine, Wake Forest School of Medicine, North Carolina; and ^bEpidemiological Cardiology Research Center, Wake Forest School of Medicine, North Carolina. Manuscript received February 23, 2020; revised manuscript received and accepted May 4, 2020.

There was no specific funding from any funding bodies that supported the present analysis.

See page 194 for disclosure information.

*Corresponding author: Tel: (336) 716-9124; fax: (336) 716-9188.

E-mail address: mjsingle@wakehealth.edu (M.J. Singleton).

processed using the GE Marquette 12-SL program. The PWA was derived from automated measurements and visually confirmed by trained ECG coders at EPICARE. ECGs were read for incident AF at the Epidemiological Cardiology Research Center, Wake Forest School of Medicine, Winston-Salem, North Carolina.

Statistical analyses were used to calculate mean \pm standard deviation for continuous variables and frequency (percentage) for categorical variables. Unadjusted analyses used analysis of variance for continuous variables and Chi-square tests for categorical variables. Two-sided p-values below 0.05 were considered to be statistically significant. Outcomes were assessed according to the intention-to-treat principle. Cox proportional hazards modeling was used to compare the risk of incident AF as a function of the baseline PWA. Initial analysis was unadjusted, with subsequent analyses iteratively adjusting for covariates believed to be of clinical importance, starting with demographics (model 1; adjusted for age, sex, and race), then history of cardiovascular disease, smoking, body mass index, treatment assignment, and mean systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and HbA1c. Time-independent proportionality assumptions were assessed by examining the Martingale residual plot. Sensitivity analyses were performed by stratifying by age above or below study median (61.9 years), sex, and race, separately. All statistical analyses were conducted at Wake Forest University School of Medicine using SAS version 9.4 (Cary, North Carolina).

Results

A total of 8,965 participants were divided into two groups based on their PWA, one with normal and the other with abnormal baseline values. The 2 groups had several similar

baseline characteristics including sex, race, systolic blood pressure, and heart rate. Participants with abnormal PWA were more likely to be older, have a lower body mass index, and a higher prevalence of cardiovascular disease. A full description of baseline characteristics is available in [Table 1](#).

Of the 8,281 participants with a baseline normal PWA, 114 (1.4%) developed incident AF whereas 31 (4.5%) of the 684 participants with abnormal PWA developed AF. After adjustment for included covariates, abnormal PWA remained associated with an increased risk of AF (hazard ratio [HR] 2.69, 95% confidence interval [CI] 1.77 to 3.97; [Table 2](#)). [Table 3](#) demonstrates a consistent heightened risk of AF in abnormal PWA participants in all prespecified subgroups of interest, except in non-whites.

As a sensitivity analysis, we explored the risk of incident AF by comparing right-axis deviation versus left-axis deviation of the P-wave. Among the 684 participants with abnormal PWA, 202 had left-axis deviation of the P-wave (median -19° , range -1° to -34°) and 482 had right-axis deviation of the P-wave (median 106° , range 76 to 142°). In the fully-adjusted Cox proportional hazards model, compared to those with normal PWA, both left-axis deviation (HR 2.13, 95% CI 1.03 to 4.39, $p = 0.04$) and right-axis deviation (HR 2.85, 95% CI 1.81 to 4.48, $p < 0.0001$) were associated with a comparable risk of incident AF.

[Figure 1](#) shows the cumulative incidence of AF throughout the study. The cumulative incidence of AF was almost twice that in participants with abnormal PWA compared with those with normal PWA.

Discussion

This study analyzing data from the ACCORD trial demonstrates an increased incidence of AF in those with abnormal PWA. Those with abnormal PWA are at least twice as

Table 1
Baseline characteristics of study participants (n = 8,965)

Variable	P-wave axis		p-Value*
	Normal (n = 8,281)	Abnormal (n = 684)	
Age (years)	62.5 \pm 6.5	64.9 \pm 7.1	< 0.0001
Men	61.2%	63.9%	0.16
White	62.2%	65.2%	0.12
Baseline cardiovascular disease	34.7%	40.2%	0.004
Smoker, Current	13.9%	17.1%	0.02
Body Mass Index (kg/m ²)	32.2 \pm 5.3	31.1 \pm 5.7	< 0.0001
Systolic Blood Pressure (mm Hg)	136.0 \pm 16.5	137.1 \pm 16.9	0.12
Diastolic blood pressure (mm Hg)	74.8 \pm 10.2	73.1 \pm 10.5	< 0.0001
Total cholesterol (mg/dl)	183.4 \pm 40.3	180.2 \pm 38.4	0.04
High-density lipoprotein (mg/dl)	41.6 \pm 11.0	42.7 \pm 12.2	0.01
Low-Density Lipoprotein (mg/dl)	105.0 \pm 33.1	103.2 \pm 32.5	0.16
Triglycerides (mg/dl)	187.6 \pm 117.8	172.0 \pm 104.7	0.0008
Hemoglobin A1c	8.28 \pm 1.00	8.25 \pm 0.99	0.50
Antihypertensive use	83.0%	83.2%	0.93
Aspirin use	55.5%	54.6%	0.65
Statin use	63.7%	65.6%	0.35
P-wave axis (degrees)	47.4 \pm 15.7	58.1 \pm 55.4	< 0.0001
Heart rate (minute ⁻¹)	69.3 \pm 11.2	69.4 \pm 11.5	0.79

Continuous variables described as mean \pm standard deviation.

Categorical variables described as frequency (percentage).

* p-Value as calculated by ANOVA for continuous and Chi-square for categorical variables.

Table 2
P-wave axis and risk of incident atrial fibrillation

P-wave axis	Cases	Follow-up(person-years)	Model 1Unadjusted		Model 2Adjusted for demographics		Model 3Fully adjusted	
			HR \pm 95% CI	p-Value	HR \pm 95% CI	p-Value	HR \pm 95% CI	p-Value
Normal (n = 8,281)	114	40,566	1.0 (reference)	—	1.0 (reference)	—	1.0 (reference)	—
Abnormal (n = 684)	31	3,290	3.34 (2.21–4.90)	<0.0001	2.69 (1.77–3.97)	<0.0001	2.65 (1.76–3.99)	<0.0001

Model 1 is unadjusted.

Model 2 adjusts for age, sex, and race.

Model 3 adjusts for the covariates in Model 2, with the addition of history of cardiovascular disease, smoking, BMI, treatment assignment, and mean SBP, total cholesterol, HDL cholesterol, and HbA1c.

Table 3
P-wave axis and risk of incident atrial fibrillation by subgroup

Subgroup		HR (95% CI)	p-Value	Interaction p-Value
Age (years)	<61.9	4.05 (1.75 – 9.37)	0.001	0.24
	\geq 61.9	2.47 (1.55 – 3.94)	0.0001	
Sex	Male	2.48 (1.54 – 3.99)	0.0002	0.65
	Female	3.35 (1.50 – 7.46)	0.003	
Race	White	2.62 (1.68 – 4.09)	< 0.0001	0.95
	Non-White	2.83 (0.94 – 8.53)	0.06	

Model adjusted for age, sex, race, history of cardiovascular disease, smoking, BMI, treatment assignment, and mean SBP, total cholesterol, HDL cholesterol, and HbA1c.




Figure 1. Cumulative incidence of atrial fibrillation stratified by P-wave axis.

likely to develop AF. This result persists after adjusting for demographics and factors reflecting increased risk of cardiovascular disease, such as mean systolic blood pressure, total cholesterol, and HbA1c, and is conserved in subgroups.

The PWA reflects the net vector of atrial depolarization specifically in the frontal plane, and this is influenced by anatomic and pathologic features of the atria.^{2,9} These findings build upon existing studies that have examined the relation between PWA and AF. One group looking at the Cardiovascular Health Study found a 17% increase in the risk of AF in abnormal PWA patients when compared with normal PWA patients.¹⁰ Another group using data from the Atherosclerosis Risk in Communities study found that 19%

of patients with abnormal PWA developed AF, and that those with abnormal PWA were 2.34 times as likely to develop incident AF (HR 2.34, 95% CI 2.12 to 2.58) in adjusted models.⁹ They also noted an increased risk of AF as the PWA decreased below 14° or went above 55° .⁹ When looking at ECG parameters after cryptogenic stroke, one group found that abnormal PWA is one of the best predictor variables for AF with an odds ratio of 3.31 (95% CI 1.49 to 7.35) in the first week after the neurovascular event.¹⁶ We found similar evidence with higher HR in our multivariate analysis when looking at PWA and AF in patients with diabetes mellitus, which itself predisposes patients to AF and cardiovascular disease.

Although literature regarding abnormal PWA exists and is growing, analysis of the directionality of axis deviation is still scarce. One group observed 56% of patients with abnormal PWA had right-axis deviation, whereas 41% had left-axis deviation when examining the prognostic role of abnormal PWA in patients undergoing revascularization or valve surgeries.¹³ However, they did note that trending survival curves suggested worse overall and cardiovascular mortality for left-axis deviation than for right.¹³ Our results suggesting a similar magnitude of association between incident AF and both left-axis deviation of the P-wave and right-axis deviation of the P-wave are additive to the existing literature. Because PWA can be an important indication of a predisposition to developing arrhythmias, it is important to understand what pathophysiology this measurement represents. Reviews discussing the substrate for AF have focused on the development of oxidative stress, atrial fibrosis and electrical autonomic remodeling.¹⁷ Echocardiography demonstrates anatomical changes in hearts with AF including increased left atrial diameter, left ventricular wall thickness, and left ventricular fractional shortening.¹⁸ One group showed that a PWA $<30^\circ$ on ECG is 90% specific, though insensitive, for detecting left atrial enlargement, which was confirmed on cardiovascular magnetic resonance imaging.¹⁹ Thus, PWA is a valuable marker of underlying progressive atrial disease and co-morbidities that are associated with subsequent incident AF.

Although no mechanism has been definitively proven to demonstrate causality between DM and developing AF, several studies have been conducted examining this relation. There are 2 main groups of observations, anatomic and electrical. Impaired glucose metabolism is associated with increased left atrial diameter.²⁰ As discussed previously, these changes can be reflected by variations in PWA and are all indicative of risk factors for developing AF in the future.

Other studies examine electrical observations. Hyperglycemia is known to cause fibrotic changes and oxidative stress, which disrupts cellular functions and can cause neuronal dysfunction.^{21,22} Impaired glucose metabolism leads to electrophysiologic changes including increased atrial activation time and lower atrial voltages.²⁰ Other electrical changes present in diabetic atria include increased susceptibility to atrial tachyarrhythmias — specifically, decreased conduction velocity, increased conduction heterogeneity, and increased action potential duration.²² Further, it has been widely accepted that DM can cause autonomic dysregulation. Briefly, a heterogeneous density of sympathetic innervation in cardiac tissue and decreased effective refractory periods are present in animal models with DM, and these can both contribute to the formation of sustained arrhythmias.^{23–25}

The strengths of this study include a large sample size and an adjusted analysis accounting for 2 other risk factors for cardiovascular disease, namely hypertension and dyslipidemia. This analysis should be considered in the context of its limitations. Our data did not include information regarding P-wave duration, P terminal sources in V1, or echocardiographic and magnetic resonance imaging data commenting on left atrial enlargement. These may be topics of future research. Abnormal PWA is a broad term that includes both right- and left-axis deviations, which can reflect different pathologies that may influence incident AF.

Although Model 3 considered risk factors for cardiovascular disease other than hyperglycemia, it is possible that some patients had other subclinical disease processes or risk factors for AF that were not accounted for. When analyzing the data by race, a small sample size of non-whites may have limited our ability to find a significant difference. Further, although our model adjusted for several confounding factors, there is the possibility that other unidentified variables played a role as well.

In conclusion, our results suggest that abnormal PWA is associated with incident AF in those with DM and that this relationship is conserved in prespecified subgroups. There may be utility in considering PWA values from routine ECGs in these patients.

Author Contributions

Karanpreet K. Dhaliwal — writing (original draft); Bharathi Upadhyaya — writing (review and editing); Elsayed Z. Soliman — conceptualization, writing (review and editing); Elijah H. Beatty — writing (review and editing); Joseph Yeboah — supervision, writing (review and editing); Prashant D. Bhawe — writing (review and editing); Matthew J. Singleton — conceptualization, methodology, formal analysis, writing (review and editing), visualization, supervision. Dr. Matthew Singleton is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

Disclosures

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

This manuscript was prepared using research materials obtained from the NHLBI Biological Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the NHLBI.

1. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet* 2015;386:154–162.
2. German DM, Kabir MM, Dewland TA, Henrikson CA, Tereshchenko LG. Atrial fibrillation predictors: importance of the electrocardiogram. *Ann Noninvasive Electrophysiol* 2016;21:20–29.
3. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. *JAMA* 1994;271:840–844.
4. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). *Am J Cardiol* 2008;101:634–638.
5. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. *Int J Cardiol* 2005;105:315–318.
6. Pallisgaard JL, Schjerving AM, Lindhardt TB, Procidia K, Hansen ML, Torp-Pedersen C, Gislason GH. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. *Eur J Prev Cardiol* 2016;23:621–627.

7. Incalzi RA, Fuso L, De Rosa M, Di Napoli A, Basso S, Pagliari G, Pistelli R. Electrocardiographic signs of chronic cor pulmonale. *Circulation* 1999;99:1600–1605.
8. Lehtonen AO, Langen VL, Puukka PJ, Kahonen M, Nieminen MS, Jula AM, Niiranen TJ. Incidence rates, correlates, and prognosis of electrocardiographic P-wave abnormalities - a nationwide population-based study. *J Electrocardiol* 2017;50:925–932.
9. Maheshwari A, Norby FL, Soliman EZ, Koene R, Rooney M, O'Neal WT, Alonso A, Chen LY. Refining prediction of atrial fibrillation risk in the general population with analysis of P-wave axis (from the Atherosclerosis Risk in Communities Study). *Am J Cardiol* 2017;120:1980–1984. a.
10. Rangel MO, O'Neal WT, Soliman EZ. Usefulness of the electrocardiographic P-wave axis as a predictor of atrial fibrillation. *Am J Cardiol* 2016;117:100–104.
11. Perez MV, Dewey FE, Marcus R, Ashley EA, Al-Ahmad AA, Wang PJ, Froelicher VF. Electrocardiographic predictors of atrial fibrillation. *Am Heart J* 2009;158:622–628.
12. Wagner GS, Lim TH, Strauss DG, Simlund J, Marriott's Practical Electrocardiography, 53. Philadelphia: Lippincott, Williams & Wilkins; 2014.
13. Lazzeroni D, Bini M, Camaiera U, Castiglioni P, Moderato L, Ugolotti PT, Brambilla L, Brambilla V, Coruzzi P. Predictive role of P-wave axis abnormalities in secondary cardiovascular prevention. *Eur J Prev Cardiol* 2017;24:1994–1999.
14. Li Y, Shah AJ, Soliman EZ. Effect of electrocardiographic P-wave axis on mortality. *Am J Cardiol* 2014;113:372–376.
15. ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. *Diabetes Care* 2016;39:701–708.
16. Acampa M, Lazzaroni PE, Guideri F, Tassi R, Andreini I, Domenichelli C, Cartocci A, Martini G. Electrocardiographic predictors of silent atrial fibrillation in cryptogenic stroke. *Heart Lung Circ* 2019;28:1664–1669.
17. Goldberger JJ, Arora R, Green D, Greenland P, Lee DC, Lloyd-Jones DM, Markl M, Ng J, Shah SJ. Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. *Circulation* 2015;132:278–291.
18. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RBS, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasani RS, Benjamin EJ. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. *Lancet* 2009;373:739–745.
19. Tsao CW, Josephson ME, Hauser TH, O'Halloran TD, Agarwal A, Manning WJ, Yeon SB. Accuracy of electrocardiographic criteria for atrial enlargement: validation with cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2008;10:7.
20. Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF, Tuan TC, Tai CT, Tsao HM, Li CH, Ueng KC, Wu TJ, Chen SA. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. *Am J Cardiol* 2010;106:1615–1620.
21. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. *World J Diabetes* 2014;5:17–39.
22. Watanabe M, Yokoshiki H, Mitsuyama H, Mizukami K, Ono T, Tsutsui H. Conduction and refractory disorders in the diabetic atrium. *Am J Physiol Heart Circ Physiol* 2012;303:H86–H95.
23. Olgin JE, Sih HJ, Hanish S, Jayachandran JV, Wu J, Zheng QH, Winkle W, Mulholland GK, Zipes DP, Hutchins G. Heterogeneous atrial denervation creates substrate for sustained atrial fibrillation. *Circulation* 1998;98:2608–2614.
24. Otake H, Suzuki H, Honda T, Maruyama Y. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. *Int Heart J* 2009;50:627–641.
25. Schmid H, Forman LA, Cao X, Sherman PS, Stevens MJ. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. *Diabetes* 1999;48:603–608.